{"product_id":"global-biomarker-partnering-terms-and-agreements-2010-2023-deal-trends-players-and-financials","title":"Global Biomarker Partnering Terms and Agreements 2010-2023: Deal trends, players and financials","description":"\u003cp\u003eGlobal Biomarker Partnering Terms and Agreements 2010-2023: Deal trends, players and financials\u003cbr\u003e\nThe Global Biomarker Partnering Terms and Agreements 2010-2023: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eTrends in biomarker partnering deals\u003cbr\u003e\nBiomarker partnering agreement structure\u003cbr\u003e\nBiomarker partnering contract documents\u003cbr\u003e\nTop biomarker deals by value\u003cbr\u003e\nMost active biomarker dealmakers\u003c\/p\u003e\n\n\u003cp\u003eThe Global Biomarker Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R\u0026amp;D, and commercialization of outcomes.\u003c\/p\u003e\n\n\u003cp\u003eThis report provides details of the latest biomarker agreements announced in the healthcare sectors.\u003c\/p\u003e\n\n\u003cp\u003eA biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.\u003c\/p\u003e\n\n\u003cp\u003eThe report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.\u003c\/p\u003e\n\n\u003cp\u003eThe report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.\u003c\/p\u003e\n\n\u003cp\u003eThe middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.\u003c\/p\u003e\n\n\u003cp\u003eOne of the key highlights of the report is that over 1,450 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R\u0026amp;D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains a comprehensive listing of all biomarker partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003c\/p\u003e\n\n\u003cp\u003eContract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides a review of the leading biomarker deals since 2010. Deals are listed by headline value, signed by big pharma, most active biomarker dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R\u0026amp;D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2010. The chapter is organized by specific biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous tables and figures that illustrate the trends and activities in biomarker partnering and dealmaking since 2010.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.\u003c\/p\u003e\n\n\u003cp\u003eKey benefits\u003c\/p\u003e\n\n\u003cp\u003eGlobal Biomarker Partnering Terms and Agreements 2010-2023: Deal trends, players and financials provides the reader with the following key benefits:\u003cbr\u003e\nIn-depth understanding of biomarker deal trends since 2011\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nDetailed access to actual biomarker contracts enter into by the leading 25 bigpharma companies\u003cbr\u003e\nAccess to most active biomarker dealmakers since 2010\u003cbr\u003e\nInsight into the terms included in a biomarker agreement, together with real world clause examples\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals           \u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Biomarker Partnering Terms and Agreements 2010-2023: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eBiomarker Partnering Terms and Agreements includes:\u003cbr\u003e\nTrends in biomarker dealmaking in the biopharma industry since 2010\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nAccess to biomarker contract documents\u003cbr\u003e\nThe leading biomarker deals by value since 2010\u003cbr\u003e\nMost active biomarker dealmakers since 2010\u003cbr\u003e\nThe leading biomarker partnering resources\u003c\/p\u003e\n\n\u003cp\u003eIn Global Biomarker Partnering Terms and Agreements 2010-2023: Deal trends, players and  financials, the available contracts are listed by:\u003cbr\u003e\nCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nDeal component type\u003cbr\u003e\nSpecific therapy target\u003c\/p\u003e\n\n\u003cp\u003eEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe Global Biomarker Partnering Terms and Agreements 2010-2023: Deal trends, players and  financials report provides comprehensive access to available deals and contract documents for over 1,450 biomarker deals. Analyzing actual contract agreements allows assessment of the following:\u003cbr\u003e\nWhat are the precise biomarker rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 900 Pages \/ MCW16229723","offer_id":47646995513650,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-biomarker-partnering-terms-and-agreements-2010-2023-deal-trends-players-and-financials","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}